This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic
obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic
resistance....
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD
(which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help
people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce
symptoms, improve q...
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance. This guideline includes recommendations on: treatment; reassessment; referral and seeking specialist ...
Wedzicha, JA;
Calverley, PMA;
Albert, RK;
Anzueto, A;
Criner, GJ;
Hurst, JR;
Miravitlles, M;
Papi, A;
Rabe, KF;
Rigau, D;
Sliwinski, P;
Tonia, T;
Vestbo, J;
Wilson, KC;
Krishnan, JA.
This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society.Comprehensive evidence syntheses were performed to summarise al...
Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico,
Aminopiridinas/uso terapéutico,
Benzamidas/uso terapéutico,
Ciclopropanos/uso terapéutico,
Fluoroquinolonas/uso terapéutico,
Macrólidos/uso terapéutico,
Antagonistas Muscarínicos/uso terapéutico,
Inhibidores de Fosfodiesterasa 4/uso terapéutico,
Progresión de la Enfermedad,
Enfermedad Pulmonar Obstructiva Crónica,
Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico,
Enfermedad Pulmonar Obstructiva Crónica/fisiopatología,
Prevención Secundaria/normas,
Agonistas de Receptores Adrenérgicos beta 2,
Aminopiridinas,
Benzamidas,
Ciclopropanos,
Fluoroquinolonas,
Macrólidos,
Antagonistas Muscarínicos,
Inhibidores de Fosfodiesterasa 4
Miravitlles, M;
Soler-Cataluña, J. J;
Calle, M;
Molina, J;
Almagro, P;
Quintano, J. A;
Trigueros, J. A;
Cosío, B. G;
Casanova, C;
Antonio Riesco, J;
Simonet, P;
Rigau, D;
Soriano, J. B;
Ancochea, J.
La enfermedad pulmonar obstructiva crónica (EPOC) presenta una gran heterogeneidad clínica, por lo que su tratamiento se debe individualizar según el nivel de riesgo y el fenotipo. La Guía española de la EPOC (GesEPOC) estableció por primera vez en 2012 unas pautas de tratamiento farmacológico bas...
Jouneau, S;
Dres, M;
Guerder, A;
Bele, N;
Bellocq, A;
Bernady, A;
Berne, G;
Bourdin, A;
Brinchault, G;
Burgel, P. R;
Carlier, N;
Chabot, F;
Chavaillon, J. M;
Cittee, J;
Claessens, Y. E;
Delclaux, B;
Deslée, G;
Ferré, A;
Gacouin, A;
Girault, C;
Ghasarossian, C;
Gouilly, P;
Gut-Gobert, C;
Gonzalez-Bermejo, J;
Jebrak, G;
Le Guillou, F;
Léveiller, G;
Lorenzo, A;
Mal, H;
Molinari, N;
Morel, H;
Morel, V;
Noel, F;
Pégliasco, H;
Perotin, J. M;
Piquet, J;
Pontier, S;
Rabbat, A;
Revest, M;
Reychler, G;
Stelianides, S;
Surpas, P;
Tattevin, P;
Roche, N.
Chronic obstructive pulmonary disease (COPD) is the chronic respiratory disease with the most important burden on public health in terms of morbidity, mortality and health costs. For patients, COPD is a major source of disability because of dyspnea, restriction in daily activities, exacerbation, risk of ...
